References
- Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 2008;26:6244–57.
- Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med 2009;361: 271–8.
- Syrjänen KJ. Annual disease burden due to human papillomavirus 16 and 18 infections in Finland. Scand J Infect Dis Suppl 2009;108:2–32.
- Annemans L, Rémy V, Lamure E, Spaepen E, Lamotte M, Muchada JP, Largeron N. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. J Med Econ 2008;11: 135–50.
- Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13:28–41.
- Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–43.
- Hiltunen-Back E. Kondylooman hoito. Duodecim 2008;124: 1121–5.
- Lacey C, Lowndes C, Shah K. HPV vaccines and screening in the prevention of cervical cancer. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24(Suppl 3):S35–41.
- Hujanen T, Kapiainen S, Tuominen U, Pekurinen M. Terveydenhuollon yksikkökustannukset Suomessa vuonna 2006. THL Työpapereita 3/2008. Helsinki: National Institute for Health and Welfare; 2008.
- Monto K, Nieminen P. Gynekologisten irtosolunäytteiden määrät ja raportointitavat Suomessa. Suomen Lääkärilehti 2005;18–19:2093–6.
- Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13:1–7.
- Insinga Ralph P. Annual productivity costs due to cervical cancer mortality in the United States, Women's Health Issues, 2006;16(5):236–242.
- Annemans L, Rémy V, Oyee J, Largeron N. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009;27: 231–45.
- Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004;191:114–20.
- Paavonen J. Mitä HPV-rokotteilta voidaan odottaa? Suomen Lääkärilehti 2009;11:1017–21.
- Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009;85:499–502.
- Chesson HW, Ekwueme DU, Saraiya M, Markowitz LA. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008;14:244–51.